{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:55:47Z","timestamp":1791449747755,"version":"4.3.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Pediatric diffuse high-grade gliomas grade 4 (pHGG-4), the most aggressive malignant primary brain tumors, are incurable and associated with poor prognosis. In most\n                      <jats:italic>pHGG-4<\/jats:italic>\n                      , meaningful genetic aberrations were rarely found, and the aggressiveness is derived from epigenetic changes and dysregulated gene expression. miRNAs are significant epigenetic regulators of gene expression that play important roles in many cancers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>miR-34a and miR-34c levels were analyzed in pHGG cell lines and tumor datasets. SF188 and KNS42 cells were transfected with miR-34a\/miR-34c mimic or scrambled oligonucleotide, and examined for viability, migration ability, and invasiveness. Expression of survival, cell cycle arrest\/progression, apoptosis, and Epithelial\u2013Mesenchymal Transition (EMT) regulating genes was examined using quantitative PCR (qPCR), western blot, and immunofluorescence assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>miR-34a and miR-34c were scarcely expressed in pHGG-4 cell lines, and miR-34c was downregulated in pHGG-4 tumor datasets. Upregulating miR-34a\/miR-34c decreased cell viability, migration ability, and invasiveness, while differentially affecting the expression of genes involved in survival, cell progression, proliferation, cell cycle arrest or death, and EMT promotion, depending on the miRNA and cell line.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      miR-34a and miR-34c are multifunctional tumor suppressors that play an important regulatory role in\n                      <jats:italic>pHGG-4<\/jats:italic>\n                      aggressiveness. Both miRNAs can serve as excellent and powerful therapeutic tools against\n                      <jats:italic>pHGG-4<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>This study revealed miR-34a and miR-34c as multifunctional suppressors of pHGG-4 tumor aggressiveness, both downregulated in disease models.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>miR-34a\/miR-34c restoration decreased cell viability, migration ability, invasiveness, and stemness marker expression<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Both miRNAs exerted similar phenotypic effects while differentially regulated gene expression in a miRNA-associated and cell line-dependent manner<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The findings reinforced that epigenetic dysregulation, rather than recurrent genetic alterations, is a central driver of pHGG-4 aggressiveness.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This work suggests the rational for potential miR-34-based therapeutic strategies in this otherwise incurable disease.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-026-05518-y","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:37:20Z","timestamp":1791448640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The potential role of miR-34a and miR-34c in the regulation of pediatric high-grade glioma 4 aggressiveness"],"prefix":"10.1038","author":[{"given":"Dikla","family":"Rogachevsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Yalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruty","family":"Mehrian-Shai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos","family":"Toren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"5518_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.21037\/atm.2018.05.11","volume":"6","author":"A Blionas","year":"2018","unstructured":"Blionas, A. et al. Paediatric gliomas: diagnosis, molecular biology and management. Ann. Transl. Med. 6, 251 (2018).","journal-title":"Ann. Transl. Med."},{"key":"5518_CR2","first-page":"99","volume":"8","author":"TP Diwanji","year":"2017","unstructured":"Diwanji, T. P., Engelman, A., Snider, J. W. & Mohindra, P. Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc. Health Med. Ther. 8, 99\u2013113 (2017).","journal-title":"Adolesc. Health Med. Ther."},{"key":"5518_CR3","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","volume":"22","author":"QT Ostrom","year":"2020","unstructured":"Ostrom, Q. T. et al. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol. 22, iv1\u2013iv96 (2020).","journal-title":"Neuro Oncol."},{"key":"5518_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/bpa.12023","volume":"23","author":"AM Fontebasso","year":"2013","unstructured":"Fontebasso, A. M., Liu, X. Y., Sturm, D. & Jabado, N. Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail. Brain Pathol. 23, 210\u2013216 (2013).","journal-title":"Brain Pathol."},{"key":"5518_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3171\/2018.10.PEDS18377","volume":"23","author":"IF Pollack","year":"2019","unstructured":"Pollack, I. F., Agnihotri, S. & Broniscer, A. Childhood brain tumors: current management, biological insights, and future directions. J. Neurosurg. Pediatr. 23, 261\u2013273 (2019).","journal-title":"J. Neurosurg. Pediatr."},{"key":"5518_CR6","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1007\/s00701-022-05301-y","volume":"164","author":"SH Torp","year":"2022","unstructured":"Torp, S. H., Solheim, O. & Skjulsvik, A. J. The WHO 2021 Classification of Central Nervous System Tumours: a practical update on what neurosurgeons need to know\u2014a minireview. Acta Neurochir. 164, 2453\u20132464 (2022).","journal-title":"Acta Neurochir."},{"key":"5518_CR7","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1200\/JCO.2017.73.0242","volume":"35","author":"D Sturm","year":"2017","unstructured":"Sturm, D., Pfister, S. M. & Jones, D. T. W. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J. Clin. Oncol. 35, 2370\u20132377 (2017).","journal-title":"J. Clin. Oncol."},{"key":"5518_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11060-017-2393-0","volume":"134","author":"S Braunstein","year":"2017","unstructured":"Braunstein, S., Raleigh, D., Bindra, R., Mueller, S. & Haas-Kogan, D. Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. J. Neurooncol. 134, 541\u2013549 (2017).","journal-title":"J. Neurooncol."},{"key":"5518_CR9","doi-asserted-by":"crossref","unstructured":"Meel, M. H., Schaper, S. A., Kaspers, G. J. L. & Hulleman, E. Signaling pathways and mesenchymal transition in pediatric high-grade glioma. Cell. Mol. Life Sci. 75, 871\u2013887 (2018).","DOI":"10.1007\/s00018-017-2714-7"},{"key":"5518_CR10","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3892\/ol.2016.4113","volume":"11","author":"Y Iwadate","year":"2016","unstructured":"Iwadate, Y. Epithelial-mesenchymal transition in glioblastoma progression. Oncol. Lett. 11, 1615\u20131620 (2016).","journal-title":"Oncol. Lett."},{"key":"5518_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/med.21408","volume":"37","author":"IC Iser","year":"2017","unstructured":"Iser, I. C., Pereira, M. B., Lenz, G. & Wink, M. R. The epithelial-to-mesenchymal transition-like process in glioblastoma: an updated systematic review and in silico investigation. Med. Res. Rev. 37, 271\u2013313 (2017).","journal-title":"Med. Res. Rev."},{"key":"5518_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neuint.2018.11.016","volume":"122","author":"IC Iser","year":"2019","unstructured":"Iser, I. C., Lenz, G. & Wink, M. R. EMT-like process in glioblastomas and reactive astrocytes. Neurochem. Int. 122, 139\u2013143 (2019).","journal-title":"Neurochem. Int."},{"key":"5518_CR13","first-page":"205","volume":"6","author":"A Diaz-Lopez","year":"2014","unstructured":"Diaz-Lopez, A., Moreno-Bueno, G. & Cano, A. Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Manag. Res. 6, 205\u2013216 (2014).","journal-title":"Cancer Manag. Res."},{"key":"5518_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s13402-017-0341-9","volume":"40","author":"GS Markopoulos","year":"2017","unstructured":"Markopoulos, G. S. et al. A step-by-step microRNA guide to cancer development and metastasis. Cell. Oncol. 40, 303\u2013339 (2017).","journal-title":"Cell. Oncol."},{"key":"5518_CR15","doi-asserted-by":"crossref","unstructured":"Mazurek, M. et al. Recent trends of microRNA significance in pediatric population glioblastoma and current knowledge of microRNA function in glioblastoma multiforme. Int. J. Mol. Sci. 21, 3046 (2020).","DOI":"10.3390\/ijms21093046"},{"key":"5518_CR16","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1002\/ijc.29610","volume":"137","author":"P Jha","year":"2015","unstructured":"Jha, P. et al. Genome-wide small noncoding RNA profiling of pediatric high-grade gliomas reveals deregulation of several miRNAs, identifies downregulation of Snorna Cluster HBII-52 and delineates H3F3A and TP53 mutant-specific miRNAs and snoRNAs. Int. J. Cancer 137, 2343\u20132353 (2015).","journal-title":"Int. J. Cancer"},{"key":"5518_CR17","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.18632\/oncotarget.28039","volume":"12","author":"M Chen","year":"2021","unstructured":"Chen, M., Medarova, Z. & Moore, A. Role of microRNAs in glioblastoma. Oncotarget 12, 1707\u20131723 (2021).","journal-title":"Oncotarget"},{"key":"5518_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/jmcb\/mju003","volume":"6","author":"M Rokavec","year":"2014","unstructured":"Rokavec, M., Li, H., Jiang, L. & Hermeking, H. The p53\/miR-34 axis in development and disease. J. Mol. Cell Biol. 6, 214\u2013230 (2014).","journal-title":"J. Mol. Cell Biol."},{"key":"5518_CR19","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3892\/etm.2012.497","volume":"3","author":"H Yamazaki","year":"2012","unstructured":"Yamazaki, H. et al. Overexpression of the miR-34 family suppresses invasive growth of malignant melanoma with the wild-type P53 gene. Exp. Ther. Med. 3, 793\u2013796 (2012).","journal-title":"Exp. Ther. Med."},{"key":"5518_CR20","doi-asserted-by":"publisher","first-page":"e5209","DOI":"10.1371\/journal.pone.0005209","volume":"4","author":"DA Bax","year":"2009","unstructured":"Bax, D. A. et al. Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS ONE 4, e5209 (2009).","journal-title":"PLoS ONE"},{"key":"5518_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2176\/nmc.27.581","volume":"27","author":"I Takeshita","year":"1987","unstructured":"Takeshita, I. et al. Characteristics of an established human glioma cell line, KNS-42. Neurol. Med. Chir. 27, 581\u2013587 (1987).","journal-title":"Neurol. Med. Chir."},{"key":"5518_CR22","doi-asserted-by":"crossref","unstructured":"Bjerke, L. et al. Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 3, 512\u2013519 (2013).","DOI":"10.1158\/2159-8290.CD-12-0426"},{"key":"5518_CR23","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/s41418-025-01481-z","volume":"32","author":"CM Croce","year":"2025","unstructured":"Croce, C. M. et al. The BCL-2 protein family: from discovery to drug development. Cell Death Differ. 32, 1369\u20131381 (2025).","journal-title":"Cell Death Differ."},{"key":"5518_CR24","doi-asserted-by":"crossref","unstructured":"Shamloo, B. & Usluer, S. p21 in cancer research. Cancers 11, 1178 (2019).","DOI":"10.3390\/cancers11081178"},{"key":"5518_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.831168","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Regulation of SIRT1 and its roles in inflammation. Front. Immunol. 13, 831168 (2022).","journal-title":"Front. Immunol."},{"key":"5518_CR26","doi-asserted-by":"publisher","first-page":"760971","DOI":"10.3389\/fonc.2021.760971","volume":"11","author":"J Xu","year":"2021","unstructured":"Xu, J., Lin, H., Wu, G., Zhu, M. & Li, M. IL-6\/STAT3 is a promising therapeutic target for hepatocellular carcinoma. Front. Oncol. 11, 760971 (2021).","journal-title":"Front. Oncol."},{"key":"5518_CR27","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.4161\/cc.9.6.10987","volume":"9","author":"F Guessous","year":"2010","unstructured":"Guessous, F. et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 9, 1031\u20131036 (2010).","journal-title":"Cell Cycle"},{"key":"5518_CR28","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1111\/febs.13342","volume":"282","author":"MK Chen","year":"2015","unstructured":"Chen, M. K. & Hung, M. C. Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases. FEBS J. 282, 3693\u20133721 (2015).","journal-title":"FEBS J."},{"key":"5518_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-019-1265-1","volume":"38","author":"J Zhou","year":"2019","unstructured":"Zhou, J., Yi, Q. & Tang, L. The roles of nuclear focal adhesion kinase (FAK) on cancer: a focused review. J. Exp. Clin. Cancer Res. 38, 250 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"5518_CR30","doi-asserted-by":"publisher","first-page":"e45475","DOI":"10.1371\/journal.pone.0045475","volume":"7","author":"M Le Mercier","year":"2012","unstructured":"Le Mercier, M. et al. A simplified approach for the molecular classification of glioblastomas. PLoS ONE 7, e45475 (2012).","journal-title":"PLoS ONE"},{"key":"5518_CR31","doi-asserted-by":"publisher","first-page":"e29722","DOI":"10.1371\/journal.pone.0029722","volume":"7","author":"S Yamamura","year":"2012","unstructured":"Yamamura, S. et al. MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS ONE 7, e29722 (2012).","journal-title":"PLoS ONE"},{"key":"5518_CR32","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.4161\/cc.10.10.15642","volume":"10","author":"R Puca","year":"2011","unstructured":"Puca, R. et al. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 10, 1679\u20131689 (2011).","journal-title":"Cell Cycle"},{"key":"5518_CR33","doi-asserted-by":"publisher","first-page":"6761","DOI":"10.1007\/s13277-015-4575-8","volume":"37","author":"H Chen","year":"2016","unstructured":"Chen, H. et al. miR-22 inhibits the proliferation, motility, and invasion of human glioblastoma cells by directly targeting SIRT1. Tumour Biol. 37, 6761\u20136768 (2016).","journal-title":"Tumour Biol."},{"key":"5518_CR34","first-page":"1977","volume":"7","author":"JK Myung","year":"2014","unstructured":"Myung, J. K., Choi, S. A., Kim, S. K., Wang, K. C. & Park, S. H. Snail plays an oncogenic role in glioblastoma by promoting epithelial mesenchymal transition. Int. J. Clin. Exp. Pathol. 7, 1977\u20131987 (2014).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"5518_CR35","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","volume":"37","author":"N Kumari","year":"2016","unstructured":"Kumari, N., Dwarakanath, B. S., Das, A. & Bhatt, A. N. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 37, 11553\u201311572 (2016).","journal-title":"Tumour Biol."},{"key":"5518_CR36","doi-asserted-by":"crossref","unstructured":"Bazzoni, R. & Bentivegna, A. Role of notch signaling pathway in glioblastoma pathogenesis. Cancers 11, 292 (2019).","DOI":"10.3390\/cancers11030292"},{"key":"5518_CR37","unstructured":"Mulcahy, E. Q. X., Colomicronn, R. R. & Abounader, R. HGF\/MET signaling in malignant brain tumors. Int. J. Mol. Sci. 21, 7546 (2020)."},{"key":"5518_CR38","doi-asserted-by":"publisher","first-page":"7569","DOI":"10.1158\/0008-5472.CAN-09-0529","volume":"69","author":"Y Li","year":"2009","unstructured":"Li, Y. et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 69, 7569\u20137576 (2009).","journal-title":"Cancer Res."},{"key":"5518_CR39","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1038\/s41388-018-0608-2","volume":"38","author":"Y Xie","year":"2019","unstructured":"Xie, Y. et al. Nuclear MET requires ARF and is inhibited by carbon nanodots through binding to phospho-tyrosine in prostate cancer. Oncogene 38, 2967\u20132983 (2019).","journal-title":"Oncogene"},{"key":"5518_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/cac2.12138","volume":"41","author":"G Pan","year":"2021","unstructured":"Pan, G., Liu, Y., Shang, L., Zhou, F. & Yang, S. EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Commun. 41, 199\u2013217 (2021).","journal-title":"Cancer Commun."},{"key":"5518_CR41","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/s12276-023-01050-9","volume":"55","author":"T Kim","year":"2023","unstructured":"Kim, T. & Croce, C. M. MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies. Exp. Mol. Med. 55, 1314\u20131321 (2023).","journal-title":"Exp. Mol. Med."},{"key":"5518_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole, R. & Slack, F. J. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 16, 203\u2013222 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"5518_CR43","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.7150\/ijms.102123","volume":"21","author":"H Qian","year":"2024","unstructured":"Qian, H. et al. Decoding the promise and challenges of miRNA-Based cancer therapies: an essential update on miR-21, miR-34, and miR-155. Int. J. Med. Sci. 21, 2781\u20132798 (2024).","journal-title":"Int. J. Med. Sci."},{"key":"5518_CR44","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","volume":"122","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br. J. Cancer 122, 1630\u20131637 (2020).","journal-title":"Br. J. Cancer"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05518-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05518-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05518-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:37:22Z","timestamp":1791448642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05518-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":44,"alternative-id":["5518"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05518-y","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}